Recent Research Funding

Our faculty secure major research grants from various National Institutes of Health as well as private sources.

Chelsie Armbruster, PhD

  • Conserved Proteus mirabilis genetic requirements for colonization of the catheterized urinary tract. Chelsie Armbruster (Co-Investigator). National Institute of Diabetes and Digestive and Kidney Diseases. $1,684,580. 9/1/2019-5/1/2024.

James Bangs, PhD

  • Secretory Protein Trafficking and Folding in African Trypanosomes. James Bangs (Principal Investigator). National Institutes of Health. $1,934,250. 7/1/2016-6/1/2021.

Piero Bianco, PhD

  • RNA EXO-Codes: A novel way to reprogram pathological exosomes. Piero Bianco (Co-Investigator). National Institute of Biomedical Imaging and Bioenengineering. $1,582,675. 7/1/2017-4/1/2021.
  • Mechanistic studies of stalled DNA replication fork rescue. Piero Bianco (Co-Investigator). NIH. $2,114,120. 6/1/2013-12/1/2017.

Ira Blader, PhD

  • TOXOPLASMA GONDII REGULATION OF HOST GABAERGIC SIGNALING. Ira Blader (Co-Principal Investigator). NIH/NIAID. 2/1/2016-1/1/2021.
  • Oxygen Sensing by the AIDS Opportunist Pathogen, Toxoplasma gondiiIra Blader (Co-Principal Investigator). NIAID/NIH. $434,763. 2/1/2015-1/1/2017.
  • GLYCOREGULATION OF SKP1 IN THE CYTOPLASM AND NUCLEUS. Ira Blader (Co-Principal Investigator). NIH/NIGMS. 1/1/2015-5/1/2019.
  • Control of Toxoplasma gondii Growth by the Host Cell Transcription Factor HIF1. Ira Blader (Co-Investigator). NIH/NIAID. 4/1/2006-1/1/2022.

Elsa Bou Ghanem, PhD

  • The role of extracellular adenosine in age-driven susceptibility to S. pneumoniae lung infection. Elsa Bou Ghanem (Principal Investigator). NATIONAL INSTITUTE ON AGING. $453,576. 9/1/2018-6/1/2021.

Anthony Campagnari, PhD

  • TARGETING M. CATARRHALIS FOR PREVENTION AND TREATMENT OF OTITIS MEDIA. Anthony Campagnari (Principal Investigator). National Institutes of Deafness and Communicative Disorders. $1,982,425. 5/1/2016-4/1/2021.
  • Pneumococcal transition from nasopharyngeal biofilm carriage to otitis media. Anthony Campagnari (Principal Investigator). NIH/NIDCD. $1,840,000. 3/1/2014-2/1/2019.

Terry Connell, PhD

  • Evaluation of a Specific Cytotoxic Agent and Identification of a New Targetable Receptor for Human TripleNegative Breast Cancer. Terry Connell (Co-Investigator). Dept. of Defense, BCRP, Breakthrough Award Levels 1. $375,000. 4/1/2018-3/1/2020.
  • Specific induction of lethal autophagy in triple-negative breast cancer cells. Terry Connell (Principal Investigator). National Cancer Institute, NIH. $275,000. 4/1/2017-3/1/2019.

Thomas Melendy, PhD

  • A novel DNA damage response that inhibits polyomavirus DNA replication. Thomas Melendy (Principal Investigator). NIAID. $436,190. 12/1/2016-11/1/2018.
  • Functional Interactions of HPV Replication Proteins E1 and E2 with Cellular DNA Proteins. Thomas Melendy (Co-Principal Investigator). NIH. $83,976. 9/1/2014-8/1/2017.
  • Evaluation and Development of E1-TopoI as a target for anti-HPV therapeutics. Thomas Melendy (Principal Investigator). NiAID. $1,739,194. 4/1/2012-3/1/2017.

John Panepinto, PhD

  • Regulation of Intrinsic Caspofungin Resistance in C. neoformans. John Panepinto (Principal Investigator). National Insitute of Allergy and Infectious Diseases. $412,353. 8/1/2018-7/1/2020.
  • Stress Responsive Reprogramming of Translating mRNA Pools in C. neoformans. John Panepinto (Principal Investigator). NIAID. $1,932,170. 5/1/2017-4/1/2022.
  • Control of Host-Induced C. neoformans Morphogenesis by Protein Arginine Methylation. John Panepinto (Principal Investigator). American Heart Association Founders Affiliate. $154,000. 1/1/2017-12/1/2019.

Spyridon Stavrou, PhD

  • A3G induced virus evolution. Spyridon Stavrou (Principal Investigator). amfAR Foundation. $50,000. 4/1/2018-3/1/2019.

Yijun Sun, PhD

  • Stress responsive reprogramming of translating mRNA pools in C. neoformans. Yijun Sun (Co-Investigator). NIH. $2,000,000. 5/1/2017-4/1/2022.
  • Methylglyoxal could mediate the relationship between infections and diabetes: a method development and feasibility study. Yijun Sun (Co-Investigator). UB-the Innovative Micro-Programs Accelerating Collaboration in Themes Program. $31,000. 7/1/2016-6/1/2017.
  • Developing advanced algorithms to address major computational challenges in current microbiome research. Yijun Sun (Principal Investigator). NIH. $973,277. 7/1/2016-6/1/2019.
  • PPI related gut microbiota dysbiosis role in diabetic nephropathy: A cross-sectional analysis. Yijun Sun (Co-Investigator). UB - GEM Pilot Study Program. $34,000. 7/1/2016-6/1/2017.
  • Pilot study of the placental, oral and gut microbiome related to pregnancy outcomes. Yijun Sun (Co-Investigator). UB - GEM Pilot Study Program. $34,000. 7/1/2016-6/1/2017.
  • The airway microbiome and lung cancer in a COPD cohort. Yijun Sun (Co-Investigator). UB - GEM Pilot Study Program. $34,000. 7/1/2016-6/1/2017.
  • Oral microbiome and periodontitis: a prospective study in postmenopausal women. Yijun Sun (Co-Investigator), Michael Buck (Co-Investigator). NIH. $4,000,000. 7/1/2014-7/1/2019.
  • Derivation of molecular signatures for accurate prostate cancer prognosis using both annotated and non-annotated tissue samples. Yijun Sun (Principal Investigator). SUNY Research Foundation. $96,495. 1/1/2014-12/1/2016.

Elizabeth Wohlfert, PhD

  • Deciphering the mechanism of how GATA3 controls the fate of regulatory T cells at mucosal sites. Elizabeth Wohlfert (Principal Investigator). Crohn‘s and Colitis Foundation of America. $268,500. 11/1/2013-11/1/2016.